Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis

Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis
link : Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis

Read also


Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis

Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis
J. C.-T. Wong, H. L.-Y. Chan, Y.-K. Tse, T. C.-F. Yip, V. W.-S. Wong and G. L.-H. Wong

Version of Record online: 21 SEP 2017 | DOI: 10.1111/apt.14341

Full Text
Download PDF
View Online

Aim
To determine the effects of statin use on the risk of liver decompensation and death among patients with chronic viral hepatitis.

Methods
We conducted a population wide cohort study using a hospital based database from the Hong Kong Hospital Authority. Adults with chronic viral hepatitis without prior liver decompensation were identified from 2000 to 2012 by International Classification of Diseases, Ninth Revision, Clinical Modification, diagnostic codes. Statin use was defined as a cumulative defined daily dose of >28. Landmark analysis was used to overcome immortal time bias. Propensity score weighting was further performed to minimise baseline confounders. Primary outcome was a composite of portal hypertension related liver decompensation events, with adjustment for death as a competing risk.

Results
A total of 69 184 patients with chronic viral hepatitis (2053 statin users and 67 131 statin non-users) were identified for the 2-year landmark analysis. After propensity score weighting of 23 baseline covariates, statin use was associated with a significant reduction in composite liver decompensation events (HR: 0.55; 95% CI: 0.36-0.83; P = .005), ascites (HR: 0.57; 95% CI: 0.36-0.92; P = .02), and a dose-dependent decrease in death (HR: 0.87; 95% CI: 0.76-0.99; P = .035) relative to no statin use.

Conclusions
Patients with chronic viral hepatitis who used statins have a reduced risk of liver decompensation and death compared to non-users in this propensity score weighted landmark analysis.

1 INTRODUCTION
2 METHODS
3 RESULTS
4 DISCUSSION
ACKNOWLEDGEMENTS
AUTHORSHIP


Thus articles Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis

that is all articles Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis the link address https://newsaninpiration.blogspot.com/2017/09/statins-reduce-risk-of-liver.html

Subscribe to receive free email updates:

0 Response to "Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis"

Post a Comment